AI disruption concerns: Discussions on social media highlight ongoing worries about artificial intelligence potentially disrupting traditional consulting models at Accenture. Analysts note the company's headcount remains elevated even as revenue growth slows. Some observers point to similar challenges faced by peers in the IT services sector.
Valuation debate intensifies: Recent posts examine Accenture's sharp drop in forward price-to-earnings ratio from prior peaks, framing it as either a compelling value opportunity or a potential trap amid technological shifts. Metrics shared include solid balance sheet quality and moderate growth projections supported by acquisitions. Market participants weigh these factors against broader sector pressures.
Technical signals emerge: Traders reference bullish institutional flows and key support levels around recent lows, suggesting possible stabilization after prior selloffs. Charts circulating show mean reversion patterns and volume spikes indicating buyer interest. Overall sentiment appears mixed as participants monitor upcoming earnings for clearer direction.
Note: This discussion summary was generated from an AI condensation of post data.
Accenture Insider Trading Activity
Accenture insiders have traded $ACN stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $ACN stock by insiders over the last 6 months:
- JOEL UNRUCH (General Counsel/Corp Secretary) has made 0 purchases and 5 sales selling 10,498 shares for an estimated $1,710,918.
- JULIE SPELLMAN SWEET (Chair and CEO) has made 0 purchases and 6 sales selling 6,057 shares for an estimated $1,461,101.
- ATSUSHI EGAWA (Co-CEO Asia Pacific) has made 0 purchases and 4 sales selling 4,872 shares for an estimated $863,044.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Accenture Congressional Stock Trading
Members of Congress have traded $ACN stock 12 times in the past 6 months. Of those trades, 4 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ACN stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAN NEWHOUSE purchased up to $15,000 on 07/10.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 2 purchases worth up to $30,000 on 06/16, 03/13 and 2 sales worth up to $30,000 on 04/14, 02/10.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 05/12.
- REPRESENTATIVE RICK W. ALLEN sold up to $50,000 on 05/08.
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 03/23.
- REPRESENTATIVE KEVIN HERN sold up to $500,000 on 03/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Accenture Hedge Fund Activity
We have seen 875 institutional investors add shares of Accenture stock to their portfolio, and 1,372 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 14,072,672 shares (+259.3%) to their portfolio in Q1 2026, for an estimated $2,774,849,464
- CAPITAL INTERNATIONAL INVESTORS removed 13,358,309 shares (-76.5%) from their portfolio in Q1 2026, for an estimated $2,633,991,368
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 6,776,149 shares (-68.9%) from their portfolio in Q2 2026, for an estimated $843,223,981
- WELLINGTON MANAGEMENT GROUP LLP removed 6,741,493 shares (-64.2%) from their portfolio in Q1 2026, for an estimated $1,329,287,589
- BLACKROCK, INC. added 5,021,626 shares (+8.8%) to their portfolio in Q2 2026, for an estimated $624,891,139
- VICTORY CAPITAL MANAGEMENT INC added 3,984,403 shares (+349.0%) to their portfolio in Q2 2026, for an estimated $495,819,109
- MORGAN STANLEY added 3,885,528 shares (+51.6%) to their portfolio in Q1 2026, for an estimated $766,148,411
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Accenture Government Contracts
We have seen $3,253,878,948 of award payments to $ACN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TITLE IV FINANCIAL AID ORIGINATION AND DISBURSEMENT (TIVOD) SYSTEMS AND CUSTOMER SERVICE TRANSITION SERVICES: $223,607,715
- FEDERALLY FACILITATED EXCHANGE (FFE): $194,675,320
- THIS TASK ORDER IS FOR AN ENTERPRISE-WIDE DIGITAL AND CUSTOMER CARE PLATFORMS AND SERVICES SOLUTION (ENTERP...: $186,193,658
- VBA DGIB SUPPORT SERVICES PURCHASE: $176,293,546
- INTEGRATED ENTERPRISE CONTRACT (IEP) THE IEP PROVIDES FULLY INTEGRATED CORE SERVICES, IT INFRASTRUCTURE, O...: $147,323,368
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Accenture Price Targets
Multiple analysts have issued price targets for $ACN recently. We have seen 17 analysts offer price targets for $ACN in the last 6 months, with a median target of $201.0.
Here are some recent targets:
- Bryan Bergin from TD Cowen set a target price of $151.0 on 06/26/2026
- Dan Dolev from Mizuho set a target price of $226.0 on 06/23/2026
- Jonathan Lee from Guggenheim set a target price of $185.0 on 06/22/2026
- James Faucette from Morgan Stanley set a target price of $130.0 on 06/22/2026
- James Friedman from Susquehanna set a target price of $140.0 on 06/22/2026
- David Paige from RBC Capital set a target price of $175.0 on 06/22/2026
- Arvind Ramnani from Truist Securities set a target price of $150.0 on 06/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
